SVB Securities Upgrades Elevation Oncology to Outperform, Raises Price Target to $8
Portfolio Pulse from richadhand@benzinga.com
SVB Securities analyst Andrew Berens upgrades Elevation Oncology (NASDAQ:ELEV) from Market Perform to Outperform and raises the price target from $5 to $8.
May 30, 2023 | 10:59 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Elevation Oncology (NASDAQ:ELEV) has been upgraded to Outperform by SVB Securities, with a raised price target of $8.
The upgrade from Market Perform to Outperform by SVB Securities analyst Andrew Berens indicates a positive outlook for Elevation Oncology. The raised price target from $5 to $8 suggests a potential upside for the stock, which could lead to a short-term increase in its price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100